文献速递血脂与心血管预防

风险评估工具指导动脉粥样硬化性心血管疾病一级预防决策:AHA与ACC特别报告

Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Special Report From the American Heart Association and American College of Cardiology.
PubMed 文献 · J Am Coll Cardiol · 2018-11-10

该特别报告总结了一级预防中定量风险评估的原理与证据,指出汇总队列方程可识别高净获益人群,但可能低估某些种族/族裔、低社会经济地位或慢性炎症患者的风险,对临界或中间风险者可加测冠状动脉钙化以重新分类风险并优化他汀选择。

要点

  • 汇总队列方程广泛验证,适用于一般美国临床人群的一级预防共享决策。
  • 对特定种族/族裔、低社会经济地位或慢性炎症患者可能系统性低估风险。
  • 临界或中间风险且决策不确定者,可测冠状动脉钙化以重新分类风险。

核心结论

  • 风险评估是一级预防的关键步骤,10年动脉粥样硬化性心血管疾病风险可识别他汀和降压治疗净获益更大、需治疗人数更少的高危患者。

研究设计与样本

  • 美国心脏协会与美国心脏病学会特别报告,总结定量风险评估的原理与证据基础。

主要发现

  • 汇总队列方程已被广泛验证,对一般美国临床人群广泛有用。
  • 汇总队列方程可能系统性低估特定种族/族裔、低社会经济地位或慢性炎症患者的风险。
  • 汇总队列方程可能高估高社会经济地位或密切参与预防保健服务患者的风险。

关键数值与推荐

  • 当前美国血压和胆固醇管理预防指南推荐使用汇总队列方程启动临床医生与患者的一级预防共享决策过程。
  • 对临界或中间风险且讨论后仍不确定者,测量冠状动脉钙化可重新分类风险估计并改善他汀治疗选择。

临床怎么用

  • 使用汇总队列方程评估10年风险以启动共享决策。
  • 对临界或中间风险且决策不确定者,考虑测量冠状动脉钙化重新分类风险。
  • 考虑风险增强因素(如家族史)以细化个体风险评估。

局限性

  • 汇总队列方程可能低估特定种族/族裔、低社会经济地位或慢性炎症患者的风险。
  • 汇总队列方程可能高估高社会经济地位或密切参与预防保健服务患者的风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Risk assessment is a critical step in the current approach to primary prevention of atherosclerotic cardiovascular disease. Knowledge of the 10-year risk for atherosclerotic cardiovascular disease identifies patients in higher-risk groups who are likely to have greater net benefit and lower number needed to treat for both statins and antihypertensive therapy. Current U.S. prevention guidelines for blood pressure and cholesterol management recommend use of the pooled cohort equations to start a process of shared decision-making between clinicians and patients in primary prevention. The pooled cohort equations have been widely validated and are broadly useful for the general U.S. clinical population. But, they may systematically underestimate risk in patients from certain racial/ethnic groups, those with lower socioeconomic status or with chronic inflammatory diseases, and overestimate risk in patients with higher socioeconomic status or who have been closely engaged with preventive healthcare services. If uncertainty remains for patients at borderline or intermediate risk, or if the patient is undecided after a patient-clinician discussion with consideration of risk enhancing factors (e.g., family history), additional testing with measurement of coronary artery calcium can be useful to reclassify risk estimates and improve selection of patients for use or avoidance of statin therapy. This special report summarizes the rationale and evidence base for quantitative risk assessment, reviews strengths and limitations of existing risk scores, discusses approaches for refining individual risk estimates for patients, and provides practical advice regarding implementation of risk assessment and decision-making strategies in clinical practice.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Lloyd-Jones DM, Braun LT, Ndumele CE, et al. Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Special Report From the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2018. PMID: 30423392. doi:10.1016/j.jacc.2018.11.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。